Overview of Relestal

Quick Facts

Property	Description
Active ingredient	Dicycloverine hydrochloride
Form	Oral Syrup, Capsule, Tablet, Injectable Solution
Pharmacological class	Antispasmodic, Anticholinergic
General purpose	Relief from painful smooth muscle spasms
Origin	Synthetic tertiary amine

What Type of Medicine is Relestal?

Relestal is a prescription-only medication primarily classified as an antispasmodic agent, belonging to the anticholinergic (antimuscarinic) pharmacological class. Its sole active ingredient is Dicycloverine hydrochloride, also known as Dicyclomine, which is chemically identified as a synthetic tertiary amine. This classification highlights the drug's specialized role in modulating involuntary physiological processes. The compound is clinically recognized for its selective action on the gastrointestinal tract smooth muscle.

How Does Dicycloverine Act as an Antispasmodic?

The general purpose of Relestal is to provide relief from the intense, painful cramping and spasms that result from excessive, uncontrolled smooth muscle activity in the digestive system. The medication exerts a characteristic dual action: it provides an anticholinergic effect by interfering with the stimulating signals of acetylcholine, and it simultaneously produces a direct musculotropic effect that physically relaxes the muscle tissue itself. This combined mechanism is supported by pharmacological data, which indicate the compound's efficiency in decreasing intestinal motility to ease functional gastrointestinal discomfort.

Available Forms of Relestal (Syrup, Capsule, and Tablet)

Dicycloverine hydrochloride is consistently supplied for systemic administration across several high-level dosage forms. This includes readily accessible oral preparations such as a syrup, capsules, and tablets. Additionally, an injectable solution is manufactured for use in circumstances where oral administration is clinically unsuitable, confirming that the active Dicycloverine hydrochloride compound remains accessible for therapeutic use.

Regulatory References

Dicyclomine: MedlinePlus Drug Information

What side effects are possible with Relestal?

Possible Side Effects and Safety Information

The safety profile of Relestal (Dicycloverine hydrochloride) is defined by its primary action as an anticholinergic agent, with adverse reactions organized by regulatory authorities into frequency and affected organ systems. The majority of documented side effects are a result of the drug's effect on smooth muscle and involuntary processes.

Officially Documented Adverse Reactions

The officially listed adverse reactions are frequently categorized by the systemic anticholinergic effect, primarily affecting the nervous, ocular, and gastrointestinal systems. Common adverse reactions documented in regulatory prescribing information include dry mouth, dizziness, blurred vision, nausea, and somnolence (drowsiness). Less common effects include constipation, nervousness, vomiting, headache, and urinary retention (difficulty in micturition).

System-Organ Class	Common Adverse Reactions
Gastrointestinal	Dry mouth, Nausea, Vomiting
Nervous System	Dizziness, Somnolence, Nervousness
Eye Disorders	Blurred vision

Serious Safety Considerations and Restrictions

Official labeling defines several serious safety concerns. These include the potential for heat prostration (fever/heat stroke due to suppressed sweating) and the risk of developing conditions such as paralytic ileus or toxic megacolon (in patients with severe ulcerative colitis). Central nervous system effects, including acute psychosis and confusion, are also listed as serious adverse reactions.

Population-Specific Safety Constraints

Regulatory documents specify explicit restrictions for certain groups. Relestal is contraindicated in infants under six months of age and in nursing mothers due to the risk of serious adverse effects on the infant. Older adults may be more susceptible to central nervous system effects like confusion. The drug is also contraindicated in patients with conditions such as glaucoma, obstructive gastrointestinal disease, or obstructive uropathy.

Overdose and Emergency Response

Overdose Manifestations and Clinical Signs

Overdose with Relestal (Dicycloverine hydrochloride) is officially documented by regulatory authorities to present with severe manifestations, primarily reflecting exaggerated anticholinergic effects. Documented clinical signs include dilated pupils, blurred vision, nausea, vomiting, and hot, dry skin. Central Nervous System involvement may result in confusion, agitation, hallucinations, and potentially seizure activity.

Severe Outcomes and Emergency Action

Severe and life-threatening outcomes are explicitly associated with overdose. These serious risks documented in regulatory labeling include paralysis (muscular weakness), profound systemic instability, and the risk of heat prostration due to impaired thermoregulation. Due to the potential for these severe manifestations, regulatory bodies mandate that emergency medical attention must be sought immediately upon suspicion of overdose.

Officially Described Management and Monitoring

Official management procedures described in regulatory labeling focus on supportive and symptomatic treatment in a clinical setting. These procedures may include gastric lavage, administration of activated charcoal, and the use of sedatives for managing CNS excitement. Hospital monitoring and clinical observation are generally required following acute overdose exposure. The label also notes that elderly patients are particularly susceptible to severe CNS effects such as delirium and psychosis in overdose situations.

Therapeutic Uses of Relestal

What Relestal Treats: Main Uses and Benefits

Relestal is commonly used to help manage the symptoms of conditions such as functional bowel/irritable bowel syndrome. This positions the medication within therapeutic domains used in situations involving certain distressing symptoms related to the digestive tract. It is applied when symptomatic relief is needed for painful visceral cramping, abdominal discomfort, and irregular gut motility—symptoms that often become disruptive during flare-ups.

The medication plays a role in managing symptoms during difficult episodes by easing distress. It may assist with maintaining a sense of stability when symptoms are more noticeable.

It is commonly used across conditions characterized by periods of heightened symptoms (like IBS) and during acute episodes of colic (renal or biliary) where the patient experiences temporary, severe visceral discomfort. The medication provides supportive relief when symptoms interfere with routine activities, contributing to improved day-to-day comfort.

Quick Fact: Relief for Painful Cramping The medication assists in managing symptoms related to physical discomfort and is relevant in contexts marked by increased discomfort and tension.

Eligibility and Restrictions for Use

Relestal (Dicycloverine hydrochloride) is formally excluded for use in specific populations due to the potential for serious harm or aggravation of pre-existing conditions. These exclusions are documented as absolute contraindications in official regulatory labeling.

Populations Who Must Not Use Relestal (Contraindicated)	Specific Condition-Based Exclusions
Infants less than 6 months of age	Obstructive disease of the gastrointestinal tract
Nursing mothers	Obstructive uropathy (urinary tract blockage)
Patients with known hypersensitivity to the drug or its ingredients	Severe ulcerative colitis
Unstable cardiovascular status in acute hemorrhage	Reflux esophagitis (inflammation of the esophagus due to acid reflux)
Myasthenia gravis	Glaucoma

Relestal should also be used with caution and requires special clinical consideration in several other patient groups. These include elderly patients who may be more susceptible to side effects, and individuals with hepatic (liver) or renal (kidney) disease. Caution is also advised for patients with coronary heart disease, congestive heart failure, high blood pressure, and known or suspected prostatic enlargement.

What should I know about interactions with other medicines?

The official interaction profile for Relestal (Dicycloverine hydrochloride) is defined by two primary regulatory categories: pharmacodynamic potentiation and pharmacokinetic interference with drug absorption.

Interaction Category	Officially Documented Effect
Pharmacodynamic Potentiation	Co-administration with other agents possessing anticholinergic activity (such as certain antiarrhythmics, antihistamines, and tricyclic antidepressants) may result in an increase in certain actions or side effects. This also applies to CNS depressants, including alcohol, which may cause additive depressant effects.
Antagonism of Effects	Relestal's anticholinergic activity may antagonize the therapeutic effects of antiglaucoma agents and medicinal products that alter gastrointestinal motility, such as metoclopramide.
Pharmacokinetic Interference	Antacids interfere with the absorption of Relestal; the simultaneous use of these agents must be avoided to prevent a clinically significant reduction in drug exposure. Additionally, Relestal may affect the gastrointestinal absorption of slowly dissolving dosage forms of Digoxin, potentially resulting in an increase in serum Digoxin concentration.

Regulatory documents emphasize the need for specific administration timing with antacids due to this absorption interference. The officially documented restrictions also include a general caution regarding the increased susceptibility of the elderly population to the additive adverse effects stemming from these documented interactions.

Mechanism of Action

How Relestal Works

Relestal is a small molecule that acts as a selective inverse agonist at the Serotonin-2A receptor (5-HT2A). It binds reversibly to the receptor, stabilizing it in an inactive conformation. This molecular interaction initiates the primary mechanistic cascade within target cells, specifically by inhibiting constitutive receptor activity and decreasing cyclic adenosine monophosphate ( cAMP) signaling.

The resulting reduction in intracellular signaling leads to a subsequent down-regulation of Corticotropin-Releasing Hormone ( CRH) production. This action effectively modulates the hypothalamic-pituitary-adrenal (HPA) axis activity, a key neuroendocrine feedback loop. The systemic consequence of HPA axis modulation includes an influence on downstream cortisol release and subsequent cortisol-mediated calcium ( Ca^2+) regulation. This effect is purely descriptive of the pharmacodynamic action.

Dosage and Administration Information

Relestal (Dicycloverine hydrochloride) is administered through one of two routes of administration: oral (using tablets, capsules, or syrup) or intramuscular (IM) injection. The injectable solution is strictly designated for intramuscular use only and is prohibited from being administered intravenously or subcutaneously.

The standard adult dosing regimen is based on the patient's response. Oral therapy typically begins at 20 mg taken four times daily (QID) and may be escalated up to a maximum single dose of 40 mg QID, not to exceed 160 mg per day. Alternative clinical regimens specify doses of 10 mg to 20 mg taken three times daily (TID). Oral doses can typically be taken with or without food.

The injectable route is reserved for temporary use when oral intake is not feasible, with the dose administered up to four times daily. This IM therapy is limited to a maximum of one to two days, after which patients are transitioned to the oral form. Clinical protocols indicate that oral treatment is discontinued if a satisfactory result is not achieved within two weeks of initiation, particularly when utilizing doses above 80 mg daily.

Population-specific usage also varies: safety and effectiveness have not been established for individuals under 18 years of age in certain clinical guidelines, while other specialized dose regimens exist for pediatric patients, detailing doses for children as young as 6 months.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Relestal

Clinical Evidence for Functional Bowel/Irritable Bowel Syndrome (IBS)

Relestal was studied for use in patients with functional symptoms of Irritable Bowel Syndrome (IBS), a condition characterized by fluctuating or episodic manifestations of discomfort. The research foundation includes Randomized Controlled Trials (RCTs), the data from which have been analyzed in Systematic Reviews and Meta-Analyses. These studies contribute to the broader evidence landscape.

Studies monitored patient-reported experiences during periods of increased symptom activity. Research describes patterns observed in the studies related to the comparison of outcomes reported by patients receiving the treatment versus those receiving an inactive substance (placebo). Evidence contributes to understanding symptom patterns over defined time intervals.

Scientific bodies have noted, however, that the foundational research relied on a limited number of trials, many of which are considered older. This means evidence quality varies across studies, leading to a recognized certainty remains low in the overall evidence base among authoritative clinical guidelines.

Study Endpoints and Measured Outcomes

Research examined various patient-reported outcomes related to systemic or functional imbalance and physical discomfort. The studies monitored outcomes related to physical discomfort, such as patient-reported outcomes describing perceived discomfort related to abdominal pain and cramping. Trials also assessed broader measures, like a patient's overall condition or global assessment of symptom change during the study period.

The data show patterns related to how symptoms evolved in the observed populations during the short-term study periods. Studies report how symptoms evolved in the observed populations, and research describes the changes measured in patient-reported outcomes for specific symptoms. The findings help contextualize how patients reported their experience when the medicine was evaluated in trials.

Research on Long-Term Use and Sustained Response

Research exploring short-term symptom changes typically observed responses over defined time intervals lasting from a few days up to several weeks. As a result, the follow-up durations were limited in the core evidence base.

Consequently, long-term effects are not fully established. There is limited information for long-term outcomes that would describe a patient's response or the durability of the observed patterns over many months or years. The available evidence focuses on research examining short-term symptom changes, and long-term outcomes are not fully established.

Research in Specific Age Groups and Populations

The medicine was evaluated in the primary clinical research, which examined adult patients diagnosed with functional bowel or irritable bowel syndrome. Therefore, the results apply only to the populations studied.

Limited information is available for research in older adults in the context of the primary efficacy trials. Similarly, data for certain groups remain insufficient, with limited research available exploring symptom patterns in pediatric populations (children and adolescents).

Research Gaps and Certainty of Evidence

Scientific assessments indicate that the evidence base has several research limitation frames, and the overall certainty remains low. The findings are often derived from trials where sample sizes were modest and that were conducted decades ago, resulting in methodological concerns noted in systematic reviews.

Due to the nature and age of the studies, the evidence contributes to understanding symptom patterns but research does not determine whether an individual will respond similarly. The research provides context but not individual predictions. The available data continue to be evaluated in updated systematic reviews that often conclude that evidence quality varies across studies.

Key Studies & References ACG Clinical Guideline: Management of Irritable Bowel Syndrome - American College of Gastroenterology (2021)

Frequently Asked Questions (FAQ)

Common questions about Relestal (FAQ)

Q: Is it normal to feel slightly nauseous when first starting Relestal?

According to the official product information, nausea is listed as a commonly documented adverse reaction. While regulatory labels do not specify if this only happens when first starting the medication, its classification as a common reaction suggests it is a known possibility associated with taking Relestal.

Q: Can I take Relestal if I am already on a blood pressure medication?

Official warnings indicate that Relestal should be used with caution in patients who have hypertension (high blood pressure). The drug also has known interactions with certain other heart medications. Due to this, a prescribing healthcare provider needs to be aware of all current heart or blood pressure medications.

Q: Does Relestal interact with common over-the-counter pain relievers like ibuprofen?

Official regulatory labels do not specifically list an interaction with common pain relievers like ibuprofen (an NSAID). However, the drug must be used carefully in patients with certain pre-existing gastrointestinal conditions. Any potential interaction should be discussed with a prescribing professional.

Q: Does Relestal affect the gastrointestinal absorption of slowly dissolving dosage forms of Digoxin?

Yes, official drug interaction information states that Relestal may interfere with the absorption of slowly dissolving forms of Digoxin. This interaction could potentially lead to higher Digoxin levels in the bloodstream. If these medications are taken together, the levels of Digoxin may need to be closely monitored by a healthcare provider.

Q: Can Relestal be used by teenagers or children?

Relestal is contraindicated (must not be used) in infants under six months of age. The U.S. regulatory information states that safety and effectiveness have not been established for individuals under 18 years of age. However, some international regulatory documents provide separate prescribing details for pediatric patients.

Q: Is Relestal safe for people with pre-existing liver or kidney issues?

The official documentation indicates that special clinical consideration is advised for patients with pre-existing hepatic (liver) or renal (kidney) disease. Use of the medication requires caution and review by a healthcare provider in these populations.

Q: Why do doctors prescribe Relestal instead of a generic drug?

Relestal is a brand name for the active ingredient Dicycloverine hydrochloride. Regulatory information focuses on the established properties and effectiveness of the compound. Whether prescribed as a brand name or a generic, the active substance is the same, and the medical effects should be consistent.

Q: Why do some people say Relestal makes them feel jittery?

The official list of adverse reactions includes central nervous system effects such as Nervousness and agitation. These are known side effects that may be interpreted or experienced by some users as feeling 'jittery' when taking the medication.

Q: What happens if I miss a dose of Relestal?

Regulatory guidance suggests that if a dose is forgotten, it is taken as soon as remembered. However, if it is almost time for the next scheduled dose, the missed dose is often skipped, and the regular schedule is resumed. Specific instructions for handling a missed dose are usually found in the patient information leaflet.

Q: Can Relestal affect my sleep patterns?

Yes, Relestal may affect sleep. The regulatory labeling lists side effects such as Somnolence (drowsiness) and, less commonly, insomnia (difficulty sleeping). Other central nervous system effects, like confusion, may also potentially disrupt normal sleep patterns.

Q: Where can I find reliable research about the effectiveness of Relestal?

Summaries of the clinical evidence that supported the drug's approval are provided in the official regulatory documents, such as the FDA labeling. These documents typically mention the types of studies, like Randomized Controlled Trials (RCTs), that were conducted.

Q: Are there any long-term safety studies available for Relestal?

The core research evidence is limited to short-term symptom changes, with generally restricted follow-up durations. Consequently, the long-term effects and outcomes of using Relestal over many months or years are not fully established by the currently available evidence base.

Q: Do I need a special prescription to get Relestal?

Relestal is officially classified as a prescription-only medication. This classification indicates that it requires a valid prescription from a licensed healthcare provider for dispensing.

Q: What should I do if the side effects of Relestal seem to be getting worse?

Official warnings emphasize that certain serious adverse reactions, such as acute psychosis, confusion, or signs of heat prostration, are listed as conditions that require immediate medical attention. If side effects worsen, or if a serious reaction is suspected, medical assistance may be required immediately.

Q: What happens if I stop taking Relestal suddenly?

Official patient information recommends speaking with a healthcare provider before stopping the drug. Stopping the medication abruptly may lead to the return of the original symptoms, such as painful cramping or spasms.

Q: Does Relestal affect a person's mood or energy levels?

Yes, official labeling lists several side effects that could potentially influence a person's mood and energy. These include central nervous system effects such as nervousness, drowsiness (somnolence), and fatigue.

Q: Is there a maximum daily amount of Relestal that can be taken?

Yes, regulatory guidelines establish dosing limits. The established maximum oral daily amount for adults is 160 milligrams.

Q: How will I know if Relestal is actually working for me?

Relestal is designed to provide relief from painful smooth muscle spasms. Official regulatory guidelines state that if a satisfactory result is not achieved within two weeks, treatment may be discontinued by a healthcare provider.

Q: What are the signs that Relestal is not right for me?

The drug is contraindicated (not recommended) if you have specific pre-existing conditions like glaucoma or obstructive gastrointestinal disease. Additionally, signs of serious side effects, such as developing acute psychosis or confusion, suggest the medication may be inappropriate.

Q: How does Relestal affect the heart rate?

Relestal may cause palpitations and tachycardia (an increased heart rate). Due to this possibility, caution is advised for patients with existing heart conditions or a history of fast heart rhythms.

How should Relestal be stored and disposed of?

Official Storage and Disposal Requirements

Relestal (Dicycloverine hydrochloride) must be stored under conditions specified in its official labeling to maintain product stability and safety.

Storage Conditions

The medication is required to be stored at temperatures not exceeding 30 C for the oral syrup, though some forms specify storage not above 25 C. The product must be protected from direct sunlight and the container must ALWAYS BE KEPT TIGHTLY CLOSED. For the oral solution, the product is stable for six months after first opening if stored correctly. As a mandatory safety rule, Relestal must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Relestal must be handled in accordance with local pharmaceutical waste requirements. To protect the environment, the medicine should not be thrown away via wastewater or household waste.

Relestal